Cobenfy(KarXT)国内价格是多少

Cobenfy (KarXT) combines xanomeline (a muscarinic agonist) with trespiumchloride (a muscarinic antagonist) to improve psychiatric symptoms by activating specific receptors in the brain.

Cobenfy (KarXT) price

As of now, it has not been officially launched for sale in mainland China.

Therefore, the drug is currently unavailable in major domestic hospitals and pharmacies, and there is no official domestic market price. For patients who are interested in using it, they usually need to obtain it through specific overseas channels or participate in clinical trials. It is recommended to pay close attention to the approval status of the National Medical Products Administration (NMPA) or consult professional medical institutions to obtain the latest listing and price information.

The pictures come from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Cobenfy (KarXT) drug interactions

1. Interactions with strong CYP2D6 inhibitors

(1), affecting drugs: such as paroxetine, fluoxetine, bupropion, etc.

(2) Mechanism of action: CYP2D6 enzyme is the main pathway for metabolizing xanomeline. Concomitant use of strong inhibitors will significantly increase the plasma concentration of xanomeline.

(3) Clinical recommendations: Close monitoring is required when used together, and be alert to the increase in side effects caused by increased blood concentration of Cobenfy.

2. Drugs that are actively secreted and excreted by the kidneys

(1) Drugs that affect: such as metformin, etc.

(2) Mechanism of action: Trespium is mainly excreted through the active secretion pathway of the kidneys. When used together, it may compete with other drugs excreted through this pathway, resulting in an increase in the blood concentration of both drugs.

(3) Clinical recommendations: It is necessary to monitor the adverse reactions of Cobenfy and related combined drugs.

3. Interaction with CYP3A4 or P-gp sensitive substrates

(1) Drugs that affect: certain oral CYP3A4 (such as some sedative-hypnotics) or P-glycoprotein (P-gp) substrates (such as digoxin).

(2) Mechanism of action: xanomeline may temporarily inhibit CYP3A4 and P-gp locally in the intestine, thereby increasing the absorption and blood concentration of these combined drugs.

(3) Clinical recommendations: When used together, be aware that the side effects of combined drugs may be enhanced.

4. With other anticholinergic drugs

(1) Influence of drugs: such as other drugs for the treatment of overactivebladder, tricyclic antidepressants, etc.

(2) Mechanism of action: Combined use will have superimposed anticholinergic effects.

(3) Clinical recommendations: It may increase the incidence and severity of side effects such as dry mouth, constipation, and urinary retention, and should be monitored.

Cobenfy (KarXT) Clinical Efficacy Evaluation

In one study, the CobenFY group also improved significantly more on CGI-S scores than the placebo group, indicating a more meaningful reduction in the overall severity of the patient's condition as assessed by clinicians.

As a drug with a new mechanism of acting on muscarinic receptors, Cobenfy provides a new option for the treatment of schizophrenia, especially for patients who have poor response or intolerance to traditional antipsychotics such as dopamine D2 receptor antagonists.